Albrecht Reichle

7.4k total citations · 2 hit papers
125 papers, 3.8k citations indexed

About

Albrecht Reichle is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Albrecht Reichle has authored 125 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 45 papers in Hematology and 38 papers in Molecular Biology. Recurrent topics in Albrecht Reichle's work include Acute Lymphoblastic Leukemia research (31 papers), Acute Myeloid Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (18 papers). Albrecht Reichle is often cited by papers focused on Acute Lymphoblastic Leukemia research (31 papers), Acute Myeloid Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (18 papers). Albrecht Reichle collaborates with scholars based in Germany, Italy and United States. Albrecht Reichle's co-authors include Nicola Gökbuget, H. Diedrich, Heinz‐August Horst, Monika Brüggemann, Gerhard Zugmaier, Ralf C. Bargou, Christoph Faul, Max S. Topp, Reinhard Andreesen and Matthias Stelljes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Albrecht Reichle

118 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

2018 516 citations Nicola Gökbuget, Hervé Dombret et al. Blood profile →
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

2014 488 citations Max S. Topp, Nicola Gökbuget et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albrecht Reichle Germany	27	1.8k	1.5k	1.4k	1.0k	657	125	3.8k
Tibor Kovacsovics United States	29	880 0.5×	1.1k 0.7×	2.3k 1.7×	1.4k 1.3×	261 0.4×	123	3.7k
Deepa Bhojwani United States	31	957 0.5×	2.2k 1.5×	1.1k 0.8×	731 0.7×	326 0.5×	111	3.5k
Felicetto Ferrara Italy	37	1.1k 0.6×	1.6k 1.1×	3.9k 2.9×	2.6k 2.6×	590 0.9×	196	5.7k
Philippe Rousselot France	46	1.3k 0.7×	1.3k 0.9×	4.7k 3.4×	1.8k 1.7×	388 0.6×	181	6.8k
Stanley R. Frankel United States	36	1.7k 1.0×	1.1k 0.7×	3.0k 2.2×	5.2k 5.1×	1.2k 1.8×	73	8.1k
K. Ganeshaguru United Kingdom	36	736 0.4×	735 0.5×	915 0.7×	1.4k 1.4×	433 0.7×	84	3.3k
Daniela Cilloni Italy	33	848 0.5×	783 0.5×	2.7k 2.0×	1.6k 1.5×	258 0.4×	181	4.4k
Eyal C. Attar United States	32	949 0.5×	424 0.3×	2.3k 1.7×	2.1k 2.0×	262 0.4×	117	4.5k
Marı́a José Calasanz Spain	43	866 0.5×	607 0.4×	2.2k 1.6×	3.0k 2.9×	774 1.2×	153	5.1k
Akil Merchant United States	24	836 0.5×	385 0.3×	818 0.6×	1.5k 1.4×	282 0.4×	84	2.5k

Countries citing papers authored by Albrecht Reichle

Since Specialization

Citations

This map shows the geographic impact of Albrecht Reichle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albrecht Reichle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albrecht Reichle more than expected).

Fields of papers citing papers by Albrecht Reichle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albrecht Reichle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albrecht Reichle. The network helps show where Albrecht Reichle may publish in the future.

Co-authorship network of co-authors of Albrecht Reichle

This figure shows the co-authorship network connecting the top 25 collaborators of Albrecht Reichle. A scholar is included among the top collaborators of Albrecht Reichle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albrecht Reichle. Albrecht Reichle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, Albrecht Reichle, & Daniel Heudobler. (2026). Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. International Journal of Molecular Sciences. 27(2). 1067–1067.

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2024). Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. Frontiers in Oncology. 13. 1289222–1289222. 3 indexed citations

Corsi, Francesca, et al.. (2023). Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition. International Journal of Molecular Sciences. 24(3). 2040–2040. 2 indexed citations

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2023). Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance. Cancers. 16(1). 180–180. 5 indexed citations

Corsi, Francesca, Stefania Briganti, Emanuele Bruni, et al.. (2022). Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer. International Journal of Molecular Sciences. 23(3). 1152–1152. 21 indexed citations

Lüke, Florian, Evelyn Orsó, Hendrik Poeck, et al.. (2020). Coronavirus disease 2019 induces multi‐lineage, morphologic changes in peripheral blood cells. SHILAP Revista de lepidopterología. 1(1). 376–383. 21 indexed citations

Gökbuget, Nicola, Hervé Dombret, Massimiliano Bonifacio, et al.. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131(14). 1522–1531. 516 indexed citations breakdown →

Heudobler, Daniel, Florian Lüke, Martin Vogelhuber, et al.. (2018). Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Frontiers in Pharmacology. 9. 1357–1357. 18 indexed citations

Bruni, Emanuele, Albrecht Reichle, Manuel Scimeca, Elena Bonanno, & Lina Ghibelli. (2018). Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction. Frontiers in Pharmacology. 9. 1307–1307. 21 indexed citations

10.

Hart, Christina, Martin Vogelhuber, Daniel Wolff, et al.. (2015). Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia. Cancer Microenvironment. 8(2). 75–92. 22 indexed citations

11.

Walter, Bernhard, Sebastian Rogenhofer, Martin Vogelhuber, et al.. (2010). Modular therapy approach in metastatic castration-refractory prostate cancer. World Journal of Urology. 28(6). 745–750. 12 indexed citations

12.

Gottfried, Eva, Sebastian Rogenhofer, Leoni A. Kunz‐Schughart, et al.. (2010). Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemotherapy and Pharmacology. 67(1). 117–126. 24 indexed citations

13.

Reichle, Albrecht & Gerhard Hildebrandt. (2009). Principles of Modular Tumor Therapy. Cancer Microenvironment. 2(S1). 227–237. 10 indexed citations

14.

Büchner, Thomas, Wolfgang E. Berdel, Claudia Haferlach, et al.. (2008). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology. 27(1). 61–69. 232 indexed citations

15.

Reichle, Albrecht & Thomas Vogt. (2008). Systems Biology: A Therapeutic Target for Tumor Therapy. Cancer Microenvironment. 1(1). 159–170. 22 indexed citations

16.

Goekbuget, Nicola, Anja Baumann, Joachim Beck, et al.. (2008). PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels. Blood. 112(11). 302–302. 20 indexed citations

17.

Wild, Peter J., Albrecht Reichle, Reinhard Andreesen, et al.. (2004). Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Clinical Cancer Research. 10(2). 556–564. 22 indexed citations

18.

Holler, Ernst, et al.. (2001). Transplantation hämatopoetischer Stammzellen aus Knochenmark und Blut. University of Regensburg Publication Server (University of Regensburg).

19.

Hiddemann, Wolfgang, Carlo Aul, Georg Maschmeyer, et al.. (1992). High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison. Hämatologie und Bluttransfusion. 28(3 Suppl 4). 412–417. 11 indexed citations

20.

Reichle, Albrecht, Martin Volkmann, Katharina Pachmann, et al.. (1990). Changes in Clonal Growth, Immunophenotype, and Morphology During a Follow-up Study of an Acute Lymphoblastic Leukemia. Hämatologie und Bluttransfusion. 33. 159–165. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact